In the survival analysis, we found that TILs has no prognostic value for DCIS (P = 0.938), DCIS-Mi (P = 0.807) and HER2+ (P = 0.379) BC patients. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.